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Introduction
Problem Identification
Heart disease is the number one cause of death in the United States (U.S.), according to
the American Heart Association (AHA).1 There are approximately 500,000 open-heart surgeries
performed yearly.2 However, many complications can arise after an open-heart procedure,
including infarction, ischemia, tamponade, dysrhythmias, cardiac failure, coagulopathy, and
hemorrhage.3 With the development of postoperative atrial fibrillation (AF) being a common
complication, in patients undergoing coronary artery bypass graft (CABG) surgery, there is a 2040% chance the patient will develop postoperative atrial fibrillation (POAF).4
When a patient develops POAF, they are at an increased risk of stroke by five times, and
it also decreases the efficacy of the heart's pumping mechanism that could lead to heart failure,
according to the National Health Services (NHS).5 Current measures to help prevent this
increased risk in CABG surgery patients include placing patients on a beta-blocker, amiodarone,
and left atrial appendage closure.6 As an anesthesia provider, what can be done to help further
reduce POAF in CABG patients? In this project, the goal is to see if intraoperative magnesium
sulfate can help further reduce the chances of developing POAF in patients undergoing CABG
surgery.
Background
CABG is a surgical procedure used to treat coronary heart disease by diverting blood
around major stenosed arteries to improve blood flow and oxygen supply to the heart. There are
approximately 500,000 CABG procedures done a year.2 However, one major complication from
a CABG procedure in POAF. POAF is new-onset atrial fibrillation with a peak effect 2-4 days
postoperative.6 The occurrence of POAF is approximately 35% in patients undergoing a cardiac
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procedure.6 It has consequences that include prolonged ICU stay, increased cost for treatment of
AF, and an additional 2-5 days in the hospital.6 POAF increases the patient risk of a stroke by 24 folds, increases reoperation due to bleeding and infections, can lead to cardiac arrest, cerebral
complications, the requirement of a permanent pacemaker, and overall increased mortality 2folds at the 30 day and 6-month mark. Currently, the management of patients on beta-blockers
has lessened the risk of patients developing POAF. The use of amiodarone and clipping of the
left atrial appendage has also decreased the patient's risk of developing complications from AF.6
As an anesthesia provider, will magnesium sulfate further reduce the patient's risk of developing
POAF after cardiac surgery?
Magnesium is an abundant mineral in the body present naturally in many foods we ingest.
According to the National Institute of Health, magnesium is also a cofactor in more than 300
reactions that regulate biochemical reactions that include protein synthesis, muscle, nerve
function, glucose control, blood pressure regulation, and help regulate normal heart rhythms.7 In
a systematic review done by Del Gobbo et al., they concluded that patients with higher serum
magnesium levels had a significantly lower risk of cardiovascular disease and were also at a
lower risk of ischemic heart disease caused by a reduced blood supply.8 With magnesium being a
natural mineral in the body and can help lower the risk of heart disease, why isn't intraoperative
magnesium used by practitioners more common?
Scope of the Problem
AF is a common complication that can occur after CABG surgery. POAF can cause
significant complications that include an increased stay at the hospital to complications leading
to death. Currently, patients are pretreated with beta-blockers to reduce the chances of
developing POAF, but the occurrence of developing this disease process is approximately 35%
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for those undergoing a cardiac procedure.6 Intraoperatively, the surgeon can clip the left atrial
appendage, a specific area that clots can form if the heart goes into AF. Once a patient develops
POAF, amiodarone can be given intravenously to convert the patient from AF to sinus rhythm.
In addition to the use of beta-blockers, magnesium sulfate can also be a helpful adjunct in
preventing POAF. A randomized double-blinded study done by Bahremand et al. concluded that
intraoperative magnesium sulfate effectively prevents postoperative arrhythmias following a
CABG procedure.9 A study was done by Naghipour et al. also concluded that intraoperative
magnesium sulfate helped reduce the incidence of all types of arrhythmias after undergoing
cardiac surgery.11 The implementation of magnesium sulfate to help reduce arrhythmias provides
a cost-effective and safe adjunct to improve patient outcomes.
Consequences of the Problem
Development of POAF after a CABG procedure can cause severe complications for the
patient. POAF causes the heart to beat irregularly, thus leading to a reduced blood flow. With a
reduced flow, formation of a clot can occur thus leading to a stroke, heart failure, and or other
cardiac-related complications. Patients who develop POAF increase their chances of a stroke by
2 to 4-fold, increase the risk of bleeding, infections, and need of a permanent pacemaker.6 On top
of these complications, patients with POAF also incur an additional bill of $10-20K for treatment
of POAF, increased intensive care unit (ICU) stay, and a prolonged hospital stay.6 Overall, in the
United States, it is estimated that over $1 billion is spent annually due to the complications of
POAF after CABG surgery.6
Knowledge Gaps
In 2011 the American College of Cardiology Foundation (ACCF) and The American
Heart Association (AHA) came out with a guideline for patients undergoing CABG surgery.
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Based on the guidelines written by Hillis et al., anesthetic management is geared toward early
recovery, early postoperative extubation, optimal levels of analgesia, and patient comfort
throughout the perioperative and postoperative period.11 Improvement in interdisciplinary
communication can enhance patient safety, and use a fellowship-trained cardiac anesthesiologist
trained in the use of the transesophageal echocardiography (TEE) to provide or supervise
anesthetic care in patients who are to be considered high risk is highly recommended.11
Historically, the management of CABG patients involves several anesthetic techniques,
including volatile agents, high-dose opioids, and preoperative medications. In the 1970s and
1980s, high-dose opioids with benzodiazepine were commonly used. Still, it later became clear
that volatile agents provided a level of protection in the setting of reperfusion of the heart and
preventative in myocardial ischemia.11
The ACCF/AHA guidelines also provide guidelines for beta-blockers at least 24 hours
before a CABG procedure to help reduce the incidence of clinical sequelae of POAF.11 To help
further decrease the incidence of POAF, intraoperative magnesium can be a cost-effective and
safe adjunct to minimize postoperative complications further. In a randomized double-blinded
clinical study done by Bahremand et al. in comparing 87 patients who received 3 grams of
magnesium intravenous versus giving 87 patients 100 ml of isotonic 0.9% fluids, there was a
reduced significance of arrhythmias in patients who received magnesium and no side effects of
the drug was observed.9
Proposal Solution
There is currently no correct way to provide anesthesia for patients who undergo CABG
procedures, but ACCF and AHA set forward a guideline. When considering an anesthetic plan
for a patient, preoperative medications, intraoperative management, and postoperative
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complications need to be evaluated. As an anesthesia provider, using magnesium sulfate
intraoperatively as an adjunct can increase patient satisfaction, decrease the patient risk of
developing POAF, reduce extended stay due to complications, and decrease the patient's cost of
care. Before a patient undergoes open-heart surgery, patients will have taken a beta-blocker 24
hours of the procedure as it is known to help reduce the chances of the patient developing POAF
and decrease the risk of sequelae related to this common complication.11 The addition of giving
IV magnesium intraoperative has also shown a significance at reducing the development of
arrhythmias postoperatively.9
Summary of the Literature
The AHA states that heart disease is the number one cause of death in the U.S. With
advancements in medicine, there are medical and surgical ways to help lessen or resolve these
complications. One way is through the CABG procedure, which diverts blood around narrowed
arteries and improves blood flow and oxygenation supply to the heart. However, there are
complications in which postoperative arrhythmias are the most common with every process. A
randomized, double-blind study by Naghipour et al. concluded that the use of magnesium
significantly reduced the occurrence of postoperative arrhythmias who underwent cardiac
surgery and overall reduced their hospital stay.10
In continuation of the use of magnesium to decrease the development of postoperative
arrhythmias, Bahremand et al. came up with a very similar conclusion. Their double-blinded
randomized control trial concluded that the use of magnesium effectively reduced the prevalence
of postoperative arrhythmias and that use of magnesium should be used prophylactically.9
Soliman and Abukhudair reached similar conclusions with their study. Soliman and Abukhudair
concluded that magnesium provided a better cardioprotective effect on patients undergoing
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cardiac surgery when compared to patients not receiving magnesium.12 They also showed a
correlation that magnesium led to a decrease in myocardial infarctions, and patients also required
less pharmacological and mechanical support post cardiac surgery.12
Through the systematic review of the literature, it was evident that magnesium helped
reduce the occurrence of POAF. In the study done by Fairley et al., they analyzed the
administration of magnesium to reduce the risk of AF after cardiac surgery. Their study
concluded that magnesium did reduce the developmental risk of arrhythmias in patients’ postcardiac surgery and recommended that magnesium be given due to the low cost, minimal risks,
and the cardiac protective effect it provides.13 One of the challenges they described in the study
was the lack of clinical uniformity, methodological uniformity, and 13 out of the 35 studies
selected were at high risk of bias.13
Lastly, the systemic review done by Salaminia et al. concluded that administration of
magnesium could be safe and cost-effective in preventing cardiac arrhythmias.14 In this study,
some limitations included lack of uniformity of the trials with the dosage of magnesium and
clinical setting, unable to subgroup and analyze patients on concurrent use of antiarrhythmic
medications.14 Lastly, the potential for bias cannot be ruled out. Salaminia et al. advise that
further research should be done about the dose and timing of giving magnesium until this method
is proven effective in preventing cardiac arrhythmias.14

Individual Studies
In the study by Naghipour et al., the authors wanted to explore ways to reduce the
number of postoperative arrhythmias after heart surgery since it is a significant and common
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complication.10 It can lead to an increased risk for morbidity and mortality. The study focused on
studying magnesium's effect on reducing postcardiac surgery arrhythmias. This double-blind,
randomized controlled trial had a total of 160 participants who were randomly assigned to one of
two groups. Group 1 received 30 mg/kg of magnesium in a 500 mL normal saline bag, while
group 2 (control group) received 500 mL of normal saline. Inclusion criteria for this study
included adults over the years of 18, normal sinus rhythm perioperative, and stable
hemodynamics. Exclusion criteria for this study included patients with chronic AF, heart rate of
less than 50, prior history of AF, previous history of cardiac surgery, recent MI of less than six
weeks, current use of antiarrhythmics, ejection fraction of less than 30%, hyperkalemia of > 2.8
mmol/L, and pulmonary arterial hypertension with a mean > 30 mmHg. Naghipour et al. utilized
Chi-square and Fisher's exact test to compare the occurrence of arrhythmias and comparison
between the two groups.10 Use independent t-test was used to compare surgical time, length of
ICU stay, and length of hospital stay. Statistical significance was set at P < 0.05 was considered a
significant finding. There was no statistical significance between the two groups regarding sex
and age (P=0.476 and P= 0.231). The average surgical time between the two groups was 5.9
hours and 5.7 hours with the P= 0.212. There were no differences between the two groups in
hemodynamic values during the postoperative course and arterial blood gas of potassium or
ionized calcium (P > 0.05). However, there was a significant difference in the incidence of
arrhythmias between the two groups (P= 0.037), with AF being the most common arrhythmia
produced postoperatively.
Naghipour et al. concluded that the implementation of magnesium decreased the
incidence of arrhythmias in patients who underwent cardiac surgery by 59%.10 Intraoperative
magnesium also significantly reduces hospital stay for patients undergoing cardiac surgery.

12
Compared to other studies similar to theirs, they tried to resolve imperfections by setting up the
study as a double-blind, randomized trial that included all types of arrhythmias such as AF,
ventricular fibrillation, ventricular tachycardia, and junctional rhythms. However, the study did
have significant limitations, including patients on chronic use of beta-blockers, classification of
the type of cardiac surgery, and failure to measure magnesium concentration in the patients
studied.
To follow, in the study done by Bahremand et al., the authors' goal was to investigate the
use of prophylactic magnesium in treating arrhythmias that occur following CABG surgery.9
This study is a randomized, double-blinded study, which consisted of 174 patients undergoing
the CABG procedure.9 Patients were divided into one of two groups. Group 1 had 87 participants
given 3 grams of magnesium in 100 mL of normal saline over 2 hours at five different times,
including 12 hours before the operation, immediately following the procedure, and postoperative
days 1,2 and 3. Group 2 (control group), which also contained 87 participants, received only 100
mL of normal saline over 2 hours five times, including 12 hours before the operation,
immediately following the procedure, and postoperative days 1,2, and 3.
Bahremand et al. concluded that arrhythmias occurrence was significantly reduced in
favor of the group who received magnesium (P= 0.013).9 While, there were no significant
differences in other operative or postoperative measurements that included sex, age, and
hemodynamics. Following the study, Bahremand et al. conclude that the prophylactic use of
magnesium effectively prevents arrhythmias in patients undergoing CABG procedures.9
However, if arrhythmias occur despite prior administration of magnesium, intervention with the
help of amiodarone is preferred to correct this complication.
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Soliman and Abukhudair (conducted a study to measure the effects of magnesium in
patients with left ventricular hypertrophy undergoing cardiac surgery to improve patient
outcomes and reduce postoperative complications.12 The study’s hypothesis is that perioperative
magnesium will improve cardiac outcomes of patients undergoing cardiac procedures. This study
is a double-blinded randomized study that includes 250 patients with left ventricular hypertrophy
undergoing CABG surgery or aortic valve replacement under cardiopulmonary bypass. Patients
were assigned to Group M (magnesium group) and Group C (control group). Group M received a
continuous magnesium infusion at 15 mg/kg/h that was started 20 minutes before induction and
maintained until after the first 24 hours postoperatively. In contrast, Group C received the same
amount in normal saline. Exclusion criteria for this study included patients with acute myocardial
infarct, mitral or tricuspid valve surgery, renal impairment, hepatic impairment, obstructive
cardiomyopathy, previous mitral valve surgery, previous tricuspid valve surgery, congestive
heart failure, and malfunctioning artificial heart valve.
Soliman and Abukhudair (2019) utilized the student’s t-test to compare numerical
variables between study groups. Use of the Chi-square test was performed for comparing
categorical data, and use of Fisher's exact test was used when the expected frequency was <5.12.
With P < 0.05, the evidence will be considered statistically significant. The two groups regarding
demographic data, comorbidities, preoperative medication, and American Society of Anesthesia
physical status score showed no significant differences. Many considerable differences between
the two groups include increased mean arterial pressure (MAP) in Group C, increased systemic
vascular resistance in Group C, and a significant decrease in pulmonary arterial blood pressure
and peripheral vascular resistance.12 Between the two groups, there were no differences in
cardiac bypass time, cross-clamping time, blood loss, transfused packed red blood cells,
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neurological complications, renal complications, and hematocrit values (P> 0.05).12 There was
also a significant difference in ICU and hospital length stay in Group M versus patients in Group
C.
Soliman and Abukhudair concluded that the implementation of magnesium produces a
cardioprotective effect on patients with left ventricular hypertrophy undergoing major cardiac
surgery.12 Magnesium also helps decrease the incidence of perioperative myocardial infarction
and arrhythmias, reduce pharmacological and mechanical support, and decrease ICU and
hospital stay. Limitations for this study included a limit to a single center in gathering
information and limited researchers on the discussion of the topic.
In the study by Fairley et al., the authors aimed to evaluate the efficacy of parenteral
magnesium as a prevention or treatment of postoperative arrhythmias in patients undergoing
cardiac surgery.13 The second central concept the authors aimed to investigate was the
association of magnesium in comparison with mortality and patient-centered care. The authors
utilized MEDLINE, CENTRAL, and EMBASE as search engines with keywords specific to their
research topic. Data from 1975 to October 2015 in the combination of search terms magnesium
and cardiothoracic surgery yielded manuscripts of interest and were revied by two authors for
potential relevance.
The results of their systematic review found that 35 publications met their inclusion
criteria. 13 studies were identified as high risk of bias, seven studies were identified as low risk
of bias, and 15 studies were identified as unclear risk of bias. Of the 35 studies, 34 publications
examined magnesium prophylaxis, and a study explored treatment. The systematic review found
that most studies were at a high or unclear risk of bias and had significant heterogeneity in
method, timing, and amount of magnesium given. They also found no mortality effects,

15
inconsistent effects, and no significant increase in adverse events. Fairley et al. also found that
magnesium was associated with reduced development of AF, with the most effective approach
being a bolus of 60 mmol of magnesium over 24 hours.13
The study concluded that the use of postoperative magnesium appears to reduce AF after
CABG surgery and is free from significant adverse events.13 However, they found insufficient
evidence that the use of magnesium will prevent other arrhythmias after cardiac surgery.13 Based
on these findings, low cost and minimal risk of magnesium therapy, administration of
magnesium to the patient after cardiac surgery is highly suggested.
In a study done by Salaminia et al., they aimed to evaluate the effect of magnesium
administration on the incidence of cardiac arrhythmias after cardiac revascularization.14 The
authors utilized SID, Magiran, IranDoc, IranMedex, MedLib, PubMed, ISI, Web of Science,
Scopus, and Google Scholar. Included in this study were studies that have the effects of
magnesium on cardiac arrhythmias and mortality after cardiac surgery in both English and Farsi,
with the time frame ranging from 1986 to 2017.
The results of their systematic review found that magnesium helped lower the occurrence
of cardiac arrhythmias compared to the placebo group. Salaminia et al. also found out that
magnesium consumption also helps decrease ventricular and supraventricular arrhythmias when
compared to the placebo group.14 However, they did find several limitations that included lack of
uniformity in the amount of magnesium given and clinical setting, insufficient data about
concurrent use of antiarrhythmics agents, and sample size and standard deviations could have
also influenced the outcomes.
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Individual Studies Chart
Author(s)

Purpose

Naghipour et
al., (2016)

To analyze the
effect of
magnesium
sulfate for the
reduction of
postcardiac
surgery
arrhythmia

Bahremand et
al., (2014)

To investigate
the use of
prophylactic
magnesium in
treating
arrhythmias to
may occur

Methodology/
Research
Design
Double-blind,
randomized
controlled trial
Level I

Double-blind
randomized
controlled trial
Level 1

Intervention(s)/
Measures

Sampling/
Setting

Primary Results

Relevant
Conclusions

A double-blind,
randomized
controlled trial
was performed on
patients who
underwent cardiac
surgery between
January and
September of
2014 to evaluate
the occurrence of
postoperative
arrhythmias in
patient who
received
magnesium (test
group) compared
to patients who
received normal
saline (control
group).
A double-blind
randomized
controlled trial
was performed on
patient who
underwent CABG
procedure. Group

For the study,
160 patients
were included.
Patient’s age
was greater than
18 years and
divided into two
groups, 80 in
group 1 and 80
in group 2.

Review of
resources
utilizations
reported a
significant
reduction in
incidence of
postoperative
development of
arrhythmias and
a decrease in
overall length of
hospital stay for
those patients
who received
magnesium
intraoperatively.

The study
concluded that
magnesium
significantly
decreased the
incidence of
arrhythmias in
patients who
underwent
cardiac surgery
by 59%. Also,
patients who
received
magnesium also
significantly
reduced their
hospital length
stay.

For the study, a
total of 174
patients
included in this
study. Patients
were divided
into two groups,

Review of the
study show that
the prevalence
of arrhythmia
prevalence was
reduced
significantly in

The study
concluded that
use magnesium
sulfate is
effective at
preventing
arrhythmia that
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postoperatively
following
CABG
procedure.

Soliman and
Abukhudair,
(2019)

To investigate
the use of
perioperative
magnesium to
improve cardiac
outcomes in
patients with left
ventricular
hypertrophy who
are undergoing
cardiac surgery
that includes

Double-blind
randomized
controlled trial
Level 1

1 (test group)
received 3 grams
of magnesium in
100 mL of normal
saline over 2
hours 12 hours
prior to surgery,
immediately after
surgery and
postoperative
days 1, 2 and 3.
Group 2 (control
group) received
only 100 mL of
normal saline at
12 hours prior to
surgery,
immediate after
surgery and
postoperative
days 1, 2, and 3.
A double-blind
randomized
contrail trial was
performed on
patients with left
ventricular
hypertrophy
undergoing
cardiac surgery.
Group M received
magnesium at 15
mg/kg/hr with the

87 in group 1
and 87 in group
2.

favor for the
group that was
pretreated with
magnesium
when compared
to the control
group. However,
there was no
difference in
operative or
postoperative
measurements
between the 2
groups.

can occur
following
CABG surgery.
Magnesium
should be used
in prophylactic
treatment since
it may decrease
arrhythmia at
low doses.

For the study, a
total of 250
patients were
divided into two
groups, 125 in
Group M and
125 in Group C.

Review of the
study showed
use of
magnesium led
to a significant
improvement of
left ventricular
systolic function
and helped
decrease
mortality
compared to

The study
concluded that
use magnesium
sulfate is
effective at
preventing
arrhythmia that
can occur
following
CABG surgery
and AVR.
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CABG or aortic
valve
replacement on
cardiopulmonary
bypass (AVR).

Fairley et al.,
(2019)

infusion starting
20 minutes prior
to induction and
maintained until
24 hours
postoperative of
the procedure.
Group C received
an equal amount
in normal saline.
To evaluate the
Systematic
Literature review
efficacy of
literature review conducted using
magnesium
Level 1
MEDLINE,
administration as
CENTRAL and
prophylaxis or
EMBASE. Search
treatment of
was aimed at
post-operative
finding studies
arrhythmias in
that identified
patients
magnesium and
undergoing
cardiothoracic
cardiac surgery
surgery

those who
received normal
saline.

Data was
collected from
1975 to October
2015. The
search was
further limited
to only adults
undergoing
cardiac surgery
and excluded
pediatric and
obstetric
studies.

Search on use of
magnesium on
cardiac surgery
patients yielded
35 studies. 34
studies
examined
prophylaxis of
magnesium in
prevention of
POAF and a
single study was
found in
exploring
treatment for
POAF. The use
of postoperative
magnesium was
associated with
a reduction of
POAF.

Post-operative
magnesium
administration
reduced the risk
of AF after
cardiac surgery
and was free of
significant
adverse events.
Due to the low
cost and
minimal risk, it
is recommended
that use of
magnesium
should be
appropriately
recommended.
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Salaminia et al.,
(2018)

To evaluate the
Systematic
effect of
literature review
magnesium
Level 1
administration
on the incidence
of cardiac
arrhythmias after
cardiac
revascularization

Literature review
conducted using
SID, Magiran,
IranDoc,
IranMedex,
MedLib, PubMed,
ISI, Web of
Science, Scopus,
and Goggle
Scholar. The
search aimed to
evaluate the effect
of magnesium
sulfate on cardiac
arrhythmias and
mortality after
cardiac surgery.

Total
participants
include 6,061
individuals,
with 2987 in the
magnesium
group and 3074
in the placebo
group.

Search on
magnesium and
the effects on
post-operative
arrythmias
yielded a total of
22 published
articles from
1986 to 2017 to
be analyzed.
The review
showed that the
total rate of
cardiac
arrhythmias was
significantly
lowered in the
group receiving
magnesium
compared to the
placebo group.

The study
concludes that
administration
of magnesium
could be safe,
cost effective in
the prevention
of cardiac
arrhythmias.
Further research
should be done
about the dose
and timing of
giving
magnesium in
the prevention
of cardiac
arrhythmias.
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Purpose/PICO Clinical Questions/Objectives
PICO Question or Purpose
Population (P): Patients undergoing CABG procedure
Intervention (I): Use of intraoperative magnesium sulfate
Comparison (C): No use of intraoperative magnesium sulfate
Outcomes (O): Decrease the occurrence of POAF
Primary DNP Project Goal
The primary goal of this project is to increase cardiac knowledge in anesthesia providers
on the use of magnesium in reducing postoperative arrhythmias in patients undergoing CABG
procedures. The site where the intervention will be implemented will include clinical areas where
the student attends. The types of anesthesia providers will consist of a medical doctor (M.D.) of
anesthesia, certified registered nurse of anesthesia (CRNA), and student registered nurse of
anesthesia (SRNA). The implantation of the goal will include a pretest to test current knowledge,
followed by a presentation, and ending with a posttest. Both pretest and posttest will be
compared. The goal is to increase anesthesia providers' understanding of magnesium and its
benefits for open-heart patients.
Goals and Outcomes
The goal is to this project is to educate anesthesia providers on the effects of magnesium
sulfate on patients undergoing open-heart surgery. The acronym SMART will be used to refer to
specific, measurable, achievable, realistic, and timely and will guide this project.15 A short
education intervention implementation will be measured with a pretest and post-examination.
The goal is achievable within the timeframe set by the academic program. The project will be
implemented throughout one semester, and results will be evaluated and disseminated the
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following semester. The goal is to collaborate with anesthesia providers with the allowed student
resources of time, intervention, pretest, and posttest. The objective will be achieved by the end of
the academic semester.
Definition of Terms
CABG
CABG is a surgical procedure used to treat coronary heart disease by diverting
blood around major stenosed arteries to improve blood flow and oxygen supply to the
heart.3
POAF
POAF is defined as new-onset AF with a peak effect of 2-4 days postoperative.6

Conceptual Framework of the Project
The conceptual framework used will be The Donabedian model. The Donabedian
measures and assesses the quality of health care organizations based on three categories:
structure, process, and outcome measure.16 The setting of this project will be presented in a
faculty lounge where all anesthesia providers will be invited to participate in the study. The
process of the project will include a pretest, educational intervention, a posttest, and evaluation.
Finally, the outcome will be measured by comparing pretest scores with posttest scores.
This project aims to improve the knowledge of anesthesia providers on the use of
magnesium and its benefits in reducing POAF in CABG patients. The theoretical framework for
this project will be based on Leininger's Culture Care Theory of Diversity and Universality.
Leininger's Theory attempts to provide culturally nursing care based on cognitively based
assistive, supportive, facilitative, or enabled acts or decisions tailored to fit the individual,
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group's or institution's cultural values, beliefs, and lifeways.17 Her Theory helped educate
providers and guided them to provide culturally congruent care. The study is based on open-heart
patients, so magnesium has many benefits overall. It can be applied to many different scenarios
to help further benefit the patient undergoing a medical procedure.
Methods
Eligibility Criteria
The studies evaluated for the literature review were chosen based on the inclusion and
exclusion criteria to discern the objectives best. Inclusion criteria included studies published
within the past ten years, written in English and with full-text availability. Exclusion criteria
included studies greater than ten years old and subjects less than 21 years old. Lastly, studies
focused on intraoperative magnesium on cardiac procedure patients were emphasized. Database
sources used for the research were accessed via the Florida International University (FIU) library
services.
Information Sources
The databases utilized for the search included The Cumulative Index to Nursing and
Allied Health Literature (CINAHL), PubMed, and Embase. The Preferred Reporting Items
further guided the literature review for Systematic Reviews and Meta-Analyses (PRISMA).
Search Strategy
The initial search yielded 46 articles. Key search terms were expanded to include:
(Magnesium) AND (Coronary Artery Bypass Graft* OR CABG* OR Coronary Artery Bypass
Graft Surgery* OR Cardiac Surgery) AND (Atrial Fibrillation* OR Afib* OR AF* OR
Arrhythmia). To ensure the most relevant and latest articles were reviewed, only articles
published within the past ten years and written in English were included. This yielded 21 articles
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for CINAHL, PubMed Central, and EMBASE. The remaining 21 articles were retrieved and sent
to the citation database for review. Five duplicate reports were removed, leaving sixteen articles
for further consideration. Titles were excluded if they did not meet inclusion criteria.
Sixteen articles were reviewed and approved for a full review of the abstract. Of the
sixteen articles, ten pieces met the criteria and were further analyzed by reading the full text.
Only the articles that met the highest level of research were chosen, leaving five elements for
summarization. Pieces that were removed included those that were meta-analysis and focused on
education.
The five articles chosen for this literature review analyzed the critical concept of
magnesium to reduce the chances of patients developing POAF after cardiac surgery. Three of
the five authors, including Naghipour et al., Bahremand et al., and Soliman and Abukhudair,
evaluated patients via a randomized controlled trial to explore effects and seek out significant
differences in patients who received and did not receive magnesium during cardiac surgery. The
remaining two studies are systematic reviews by Fairley et al. and Salaminia et al.

Methodology
Setting and Participants
This study will take place at an appointed facility per school policy. The facility will be in
South Florida, and the providers themselves and the population they serve are of diverse
backgrounds. The types of providers included in this study will be MDs, CRNAs, and SRNAs.
Description of Approach and Project Procedures
The DNP project intervention will begin with participants taking a pretest, followed by a
program, and end with a posttest. Data will be collected before the educational intervention to
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include demographics, years of practice, and previous training history. The training is expected
to have a duration of 20 minutes.
Protection of Human Subjects
All anesthesia providers will be invited to participate via email. Suppose the Institutional
Review Board (IRB) determines that this study poses more than minimal risk. In that case,
participants will be consented via a HIPAA compliant online survey using such platforms as
Qualtrics or Survey Monkey. Participants will have the right to withdraw their consent at any
time. Benefits of participation will include improving knowledge, self-reflection, and how it
affects their care. No identifiable data will be collected during the study. Data will be stored in a
password-protected online database and only accessible to the primary investigator.
Data Collection
Demographic data to be collected will include gender, race, ethnicity, and education.
Participants will be asked to provide numbers of years working in their field of practice. And
finally, pretest and posttest scores will be recorded and documented.
Data Management and Analysis Plan
Data will be stored in a database, password-protected, and only used by the primary
investigator. No direct identifiers will be collected. Pretest and posttest scores will be collected,
scored, and compared before and after the intervention.

Results
Demographics
The demographics are shown in Table 1.
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Table 1 Participant Demographics
Participant Demographics
Total Participants
8 (100%)
Gender
Male
4 (50%)
Female
4 (50%)
Age
20-40
4 (50%)
41-60
4 (50%)
Ethnicity
Hispanic
3 (37.5%)
Caucasian
2 (25%)
African American
1 (12.5%)
Other
2 (25%)
Medical Position
CRNA
8 (100%)
MD
0 (0%)
Education
Masters
6 (75%)
Doctorate
2 (25%)
Years Of Experience
0-2 years
1 (12.5%)
3-5 years
2 (25%)
6-10 years
3 (37.5%)
11 years or more
2 (25%)

There were 8 participants in the pretest and posttest demographics and all 8 participants
completed the study. The participants were male (n=4, 50%) and female (n=4, 50%). There were
also a range of ethnicities represented: Hispanic (n=3, 37.5%), Caucasian (n=2, 25%), African
American (n=1, 12.5%) and other (n=2, 25%). Information was obtained regarding the
participant’s role at the hospital. It was found that only CRNAs (n=8, 100%) participated in the
study. The participants were questioned about the length of time practicing, findings that the
practice period ranged: 0-2 years (n=1, 12.5%), 3-5 years (n=2, 25%), 6-10 years (n=3, 37.5%),
and 11 years or more (n=2, 25%).
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Pretest Magnesium and Cardiac Procedures
This section contains information regarding pretest knowledge of use of magnesium to
decrease risk of postoperative arrhythmias in patients undergoing cardiac procedures. All
participants (100%) were aware that the number one cause of death in the United States is heart
disease. There were slightly more participants (62.5%) who knew about the cost associated with
open heart surgery. Slightly less participants (37.5%) understood the percentage chance of a
patient who underwent CABG surgery to develop arrythmias postoperatively. Half of the
participants (50%) were able to identify the increased risk of development of stroke after
surgery. All participants (100%) were aware of the complications of POAF. A minimal number
of participants (12.5%) were able to identify how many cofactors magnesium is involved in. All
participants (100%) had knowledge of magnesium being able to regulate biochemical reactions.
Most participants (87.5%) understood adverse drug reactions to magnesium sulfate. Most
participants (87.5%) can understand that magnesium is not the drug of choice of POAF. Finally,
half of the participants (50%) were able to identify which channel magnesium effect of the heart.
Pretest Preventative Measures
Most participants (87.5%) were neither likely nor unlikely to use magnesium as a
preventative measure for preventing POAF in patients who underwent a CABG procedure.
However, this does not mean participants were convinced one way or the other. Based on the
pretest, most participants remained neutral about this topic.
Pretest Recommendation to Apply in Practice
All participants (100%) were neither likely nor unlikely to recommend magnesium as a
preventative measure to prevent development of POAF.
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Posttest Magnesium and Cardiac Procedures
This section contains information regarding posttest knowledge of use of magnesium to
decrease risk of postoperative arrhythmias in patients undergoing cardiac procedures. All
participants (100%) were aware that the number one cause of death in the United States is heart
disease. All participants (100%) knew about the cost associated with open heart surgery. Most
participants (62.5%) understood the percentage chance of a patient who underwent CABG
surgery to develop arrythmias postoperatively. Most of the participants (87.5%) were able to
identify the increased risk of development of stroke after surgery. Almost all participants
(87.5%) were aware of the complications of POAF. A minimal number of participants (37.5%)
were able to identify how many cofactors magnesium is involved in. All participants (100%) had
knowledge of magnesium being able to regulate biochemical reactions. All participants (100%)
understood adverse drug reactions to magnesium sulfate. All participants (100%) can understand
that magnesium is not the drug of choice of POAF. Finally, most of the participants (75%) were
able to identify which channel magnesium effect of the heart.
Posttest Preventative Measures
Half of the participants (50%) were neither likely nor unlikely to use magnesium as a
preventative measure for preventing POAF in patients who underwent a CABG procedure.
Based on the posttest, participants varied more than the pretest. After the posttest, participants
had more of an opinion on use of magnesium to prevent measures for POAF.
Posttest Recommendation to Apply in Practice
Half of the participants (50%) were neither likely nor unlikely to recommend magnesium
as a preventative measure to prevent development of POAF. Compared to the pretest, there was
more variability when recommending magnesium to other colleagues.
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Table 2 Pretest/Posttest Knowledge

Pretest/Posttest Knowledge
9
8
7
6
5
4
3
2
1
0

Pretest

Posttest

Table 3 Average Overall Pretest Versus Posttest Score

Average Overall Pretest Versus Posttest Score

8
6.8

7
6

5.6

5
4
3
2
1
0

Pretest
Posttest
Average Overall Points
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Table 4 Preventative Measure

How likely are you to use magnesium sulfate as a
preventive measure for preventing POAF in patients who
undergo CABG surgery?
8

7

7
6
5

4

4
3

2

2
1

1
0

1
0

0

1
0

0
Extremely unlikely

Somehwat unlikely

Neither likely nor
unlikely
Pretest

Somehwat likely

Extremely likely

Posttest

Table 5 Recommendation to Apply in Practice

How likely are you to recommend magnesium sulfate for
patients undergoing CABG procedures to prevent
development of POAF?
9

8

8
7
6
5

4

4
3

2

2
1

1
0

0

0

0

1
0

0
Extremely unlikely

Somehwat unlikely

Neither likely nor
unlikely
Pretest

Posttest

Somehwat likely

Extremely likely
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Discussion
Limitations
Limitations include small sample size, single system, email invitation, self-selection bias,
and online PowerPoint delivery. A bigger sample size would be recommended for a more
accurate representation of the population. The sample population also came from a single health
care group in which only CRNAs participated in the survey. Other anesthesia providers included
in this population would be MDAs and AAs. Since the invitation was sent out via email, not all
providers will check their emails daily, and with the survey being entirely voluntary, selfselection bias is also present. With the application of an online PowerPoint delivery, scores were
improved when comparing pretest and posttest.

Discussion of results with Implications to Advanced Nursing Practice
The use of a valid hypothesis can have many positive implications. Use of magnesium to
help reduce POAF in CABG patients, however as a health care provider, how will this
information help improve the quality of care given to other patients. The use of magnesium has
many benefits, including antiarrhythmic, a muscle relaxant, helps as an adjunct to anesthesia,
helps with constipation, acid reflux, and many more things. A better understanding of medication
can help provide a better outcome for patients undergoing surgery. The effect of this training was
to demonstrate that a short intervention would improve knowledge and provide a positive impact
for the anesthesia provider. This current study can enhance the existing literature, which lacks
the use of intraoperative magnesium in preventing POAF in patients undergoing CABG surgery.
The sample of this population will be unique because of the multicultural diversity of the Florida
population and its collaboration with MDs, CRNAs, and SRNAs.
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Conclusion
Overall, magnesium should be used prophylactically to prevent postoperative arrhythmias
in patients undergoing cardiac surgery. This measure should be set as a standard of practice
unless contraindicated to improve patient outcomes and patient safety. This effort will help
reduce the prevalence of postoperative arrhythmias post-surgery, leading to fewer complications
such as stroke, infarction, ischemia, tamponade, dysrhythmias, cardiac failure, coagulopathy,
bleeding, and mortality. The patient will also have a reduced stay in the ICU, hospital length
stays, and require a reduced number of medications postoperatively.
In conclusion, the information obtained from the five studies will help establish the
groundwork for a quality improvement project that focuses on reducing postoperative
arrhythmias in patients undergoing cardiac surgery. By utilizing the latest evidence-based
research, quality improvement is expected to improve surgical outcomes and patient satisfaction.
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